BioSpectrum the business of Bio & Health Sciences ASIA EDITION

Japan's Daiichi Sankyo divests certain cardiovascular products, shifting focus to oncology

January 19, 2022 | News

Divesting select products to US-based Cosette Pharmaceuticals



Japan-based pharmaceutical firm Daiichi Sankyo has entered into an agreement with Cosette Pharmaceuticals, Inc. whereby Daiichi Sankyo divested and Cosette acquired rights for manufacturing, commercialization, and certain other rights for the following products in the US.:

AZOR® (amlodipine/olmesartan medoxomil); BENICAR® (olmesartan medoxomil); BENICAR HCT® (olmesartan medoxomil/hydrochlorothiazide); EFFIENT® (prasugrel); EVOXAC® (cevimeline HCL); TRIBENZOR® (olmesartan medoxomil/amlodipine/hydrochlorothiazide); WELCHOL® (colesevelam HCL) tablets; and WELCHOL® (colesevelam HCL) Oral Suspension.

“As part of our 2030 vision of becoming a global top 10 leader in oncology, we are shifting our structure to focus on our oncology portfolio in the US, while ensuring these legacy medicines continue to be available to the patients who rely on them,” said Ken Keller, President & CEO, Daiichi Sankyo, Inc.

The agreement outlines a 30-month transition period during which Daiichi Sankyo and Cosette Pharmaceuticals will transfer responsibilities for the manufacture, supply and commercialization of these products, including quality assurance, pharmacovigilance and regulatory matters.